Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Search
CLINSQUARE: CLINICAL RESEARCH COURSES
Thursday, March 28, 2024
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Facebook
Twitter
CLINSQUARE: Clinical Rsearch Courses by LIFEPRONOW
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Search
Home
Latest Pharma-News
Latest Pharma-News
Latest Pharma-News
FDA Takes Steps to Ensure Safety of Cinnamon Products Sold in the US
admin
-
March 8, 2024
Latest Pharma-News
FDA Clears First Over-the-Counter Continuous Glucose Monitor
admin
-
March 8, 2024
Latest Pharma-News
FDA, Industry Actions End Sales of PFAS Used in US Food Packaging
admin
-
March 1, 2024
Latest Pharma-News
Regulatory Applications Accepted in the U.S. and Japan for BMS Breyanzi in Relapsed or Refractory FL and Relapsed or Refractory MCL
admin
-
February 3, 2024
Latest Pharma-News
BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for Primary Photoreceptor Diseases
admin
-
February 1, 2024
Latest Pharma-News
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)
admin
-
February 19, 2020
0
Latest Pharma-News
MediciNova Receives Notice of Allowance from the Japan Patent Office for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH...
admin
-
February 19, 2020
0
Latest Pharma-News
Arctoris announces a formal partnership with Molecule to tackle the innovation crisis in the drug discovery and development
admin
-
February 18, 2020
0
Latest Pharma-News
Lupin received approval from U.S. FDA and launches Moxifloxacin Ophthalmic Solution USP 0.5%
admin
-
February 18, 2020
0
Latest Pharma-News
FDA grant approval for GSK’s Voltaren Arthritis Pain for over-the-counter use in the United States
admin
-
February 18, 2020
0
Latest Pharma-News
Health ministry issues notification to regulate all the medical devices under D&C Act from April 1, 2020
admin
-
February 17, 2020
0
Latest Pharma-News
New Phase IIIb Interim Data from the STARDUST Study Shows about Two-Thirds of Patients with Moderately to Severely Active Crohn’s Disease Achieved Clinical Remission...
admin
-
February 17, 2020
0
Latest Pharma-News
Deciphera Pharmaceuticals Announces U.S. FDA Acceptance of NDA and Priority Review for Ripretinib in the Patients with Advanced Gastrointestinal Stromal Tumors
admin
-
February 17, 2020
0
Latest Pharma-News
U.S.FDA Accepts for Priority Review Bristol-Myers Squibb’s Biologics License Application for the Lisocabtagene Maraleucel (liso-cel) for the Adult Patients with Relapsed or Refractory Large...
admin
-
February 14, 2020
0
Latest Pharma-News
Merck’s Checkpoint Inhibitor Keytruda (pembrolizumab) Hits Another Mark in Breast Cancer
admin
-
February 14, 2020
0
Latest Pharma-News
Eli Lilly Announces Topline Results for the Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study
admin
-
February 14, 2020
0
Latest Pharma-News
Novartis announces MET inhibitor capmatinib, the first potential treatment for the METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
admin
-
February 13, 2020
1
1
...
127
128
129
...
144
Page 128 of 144
- Advertisment -
Most Read
FDA Takes Steps to Ensure Safety of Cinnamon Products Sold in the US
March 8, 2024
FDA Clears First Over-the-Counter Continuous Glucose Monitor
March 8, 2024
FDA, Industry Actions End Sales of PFAS Used in US Food Packaging
March 1, 2024
Regulatory Applications Accepted in the U.S. and Japan for BMS Breyanzi in Relapsed or Refractory FL and Relapsed or Refractory MCL
February 3, 2024